Insider Trading Activity Clearside Biomedical Inc (NASDAQ:CLSD) – Insider Sold 8,000 shares of Stock

24

Insider Trading Activity For Clearside Biomedical Inc (NASDAQ:CLSD)

Daniel H White , Insider of Clearside Biomedical Inc (NASDAQ:CLSD) reportedly Sold 8,000 shares of the company’s stock at an average price of 8.41 for a total transaction amount of $67,280.00 SEC Form

Insider Trading History For Clearside Biomedical Inc (NASDAQ:CLSD)

  • On 6/7/2016 Venture Advisors Iv S Hatteras, Major Shareholder, bought 414,286 with an average share price of $7.00 per share and the total transaction amounting to $2,900,002.00. View SEC Filing
  • On 6/7/2016 Clay Thorp, Director, sold 138 with an average share price of $7.00 per share and the total transaction amounting to $966.00. View SEC Filing
  • On 1/19/2017 Venture Advisors Iii Hatteras, Insider, sold 25,301 with an average share price of $8.63 per share and the total transaction amounting to $218,347.63. View SEC Filing
  • On 1/20/2017 Clay Thorp, Director, sold 68,485 with an average share price of $8.53 per share and the total transaction amounting to $584,177.05. View SEC Filing
  • On 2/17/2017 Clay Thorp, Director, sold 41,485 with an average share price of $7.60 per share and the total transaction amounting to $315,286.00. View SEC Filing
  • On 2/22/2017 Clay Thorp, Director, sold 27,000 with an average share price of $7.55 per share and the total transaction amounting to $203,850.00. View SEC Filing
  • On 3/16/2017 Clay Thorp, Director, sold 68,485 with an average share price of $6.56 per share and the total transaction amounting to $449,261.60. View SEC Filing
  • Analyst Ratings For Clearside Biomedical Inc (NASDAQ:CLSD)
    These are 5 Buy Ratings .
    The current consensus rating for Clearside Biomedical Inc (NASDAQ:CLSD) is Buy (Score: 3.00) with a consensus target price of $20.40 , a potential (154.05% upside)

    Analyst Ratings History For Clearside Biomedical Inc (NASDAQ:CLSD)

    • On 10/24/2016 Stifel Nicolaus Boost Price Target of rating Buy with a price target of $13.00 to $23.00
    • On 2/24/2017 JPMorgan Chase & Co. Initiated Coverage of rating Overweight to Overweight with a price target of $19.00
    • On 3/14/2017 Needham & Company LLC Lower Price Target of rating Buy with a price target of $18.00
    • On 4/20/2017 Wedbush Reiterated Rating Outperform with a price target of $27.00
    • On 5/11/2017 Cowen and Company Reiterated Rating Buy with a price target of $15.00

    About Clearside Biomedical Inc (NASDAQ:CLSD)
    Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

    Recent Trading Activity for Clearside Biomedical Inc (NASDAQ:CLSD)
    Shares of Clearside Biomedical Inc closed the previous trading session at 8.03 down -0.44 -5.19% with 115,106 shares trading hands.

    An ad to help with our costs